WOOJUNG BIO Inc (215380) - Cash Flow Conversion Efficiency
Based on the latest financial reports, WOOJUNG BIO Inc (215380) has a cash flow conversion efficiency ratio of -0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-809.75 Million ≈ $-548.76K USD) by net assets (₩24.58 Billion ≈ $16.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
WOOJUNG BIO Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how WOOJUNG BIO Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 215380 total debt and obligations for a breakdown of total debt and financial obligations.
WOOJUNG BIO Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of WOOJUNG BIO Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gabriel Resources Ltd
V:GBU
|
0.080x |
|
Molecure S.A.
WAR:MOC
|
0.266x |
|
Alticast Corporation
KQ:085810
|
0.104x |
|
Labiana Health S.A.
MC:LAB
|
0.604x |
|
EasyJet PLC
LSE:EZJ
|
0.265x |
|
Far East Gold Ltd
AU:FEG
|
-0.093x |
|
RenovoRx Inc
NASDAQ:RNXT
|
-0.281x |
|
TRF Limited
NSE:TRF
|
0.128x |
Annual Cash Flow Conversion Efficiency for WOOJUNG BIO Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of WOOJUNG BIO Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see WOOJUNG BIO Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩29.37 Billion ≈ $19.91 Million |
₩-1.13 Billion ≈ $-763.37K |
-0.038x | +73.85% |
| 2023-12-31 | ₩21.97 Billion ≈ $14.89 Million |
₩-3.22 Billion ≈ $-2.18 Million |
-0.147x | -274.16% |
| 2022-12-31 | ₩29.72 Billion ≈ $20.14 Million |
₩2.50 Billion ≈ $1.70 Million |
0.084x | +53.31% |
| 2021-12-31 | ₩31.46 Billion ≈ $21.32 Million |
₩1.73 Billion ≈ $1.17 Million |
0.055x | +117.95% |
| 2020-12-31 | ₩28.03 Billion ≈ $19.00 Million |
₩-8.57 Billion ≈ $-5.81 Million |
-0.306x | -4007.26% |
| 2019-12-31 | ₩26.66 Billion ≈ $18.07 Million |
₩208.72 Million ≈ $141.45K |
0.008x | +134.30% |
| 2018-12-31 | ₩21.20 Billion ≈ $14.37 Million |
₩-483.80 Million ≈ $-327.87K |
-0.023x | +82.39% |
| 2017-12-31 | ₩18.32 Billion ≈ $12.42 Million |
₩-2.38 Billion ≈ $-1.61 Million |
-0.130x | +5.85% |
| 2016-12-31 | ₩10.57 Billion ≈ $7.16 Million |
₩-1.46 Billion ≈ $-986.04K |
-0.138x | -- |
About WOOJUNG BIO Inc
WOOJUNG BIO, Inc. provides non-clinical research agency services. The company was founded in 1989 and is based in Hwaseong-si, South Korea.